Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Targets |
IC50: 2.7 nM (HIV-1 integrase)[1]
|
---|---|
ln Vitro |
Dolutegravir (S/GSK1349572) has an EC50 of 0.51 nM against HIV-1 in PBMCs, 0.71 nM in MT-4 cells, and 2.2 nM in the pseudotyped self-inactivating virus (PHIV) assay. Dolutegravir's 50% cytotoxic concentrations (CC50) in proliferating IM-9, U-937, MT-4, and Molt-4 cells are, in order, 4.8, 7.0, 14, and 15 μM. The CC50 values in unstimulated and stimulated PBMCs are 189 μM and 52 μM, in that order. Dolutegravir's 0.51 nM EC50 against HIV-1 in PBMCs indicates that a cell-based therapeutic index of at least 9,400 is required[1].
|
ln Vivo |
In rats (0.23 mL/min/kg) and monkeys (2.12 mL/min/kg), the plasma clearance after a single intravenous (IV) dose of dolutegravir is low. Both the rat and monkey have half-lives of roughly six hours, and their steady-state volume of distribution (VSS) is small. When given orally as a solution to one male monkey and five fast-fasting rats, dolutegravir is highly bioavailable and quickly absorbed (75.6 and 87.0%, respectively). After oral administration of a suspension to non-fasted rats up to 250 mg/kg and non-fasted monkeys up to 50 mg/kg, dolutegravir exposure (Cmax and AUC) increased with increasing dose, albeit the increase is less than proportional[2].
|
References |
[1]. Kobayashi M, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011 Feb;55(2):813-21.
[2]. Moss L, et al. The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. Xenobiotica. 2015 Jan;45(1):60-70. [3]. Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72 |
Molecular Formula |
C20H18F2N3NAO5
|
---|---|
Molecular Weight |
441.36
|
CAS # |
1051375-19-9
|
Related CAS # |
Dolutegravir;1051375-16-6
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
[Na+].FC1C([H])=C(C([H])=C([H])C=1C([H])([H])N([H])C(C1C(C(=C2C(N3[C@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])O[C@@]3([H])C([H])([H])N2C=1[H])=O)[O-])=O)=O)F
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 4.5 mg/mL (10.20 mM)
H2O : < 0.1 mg/mL |
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2657 mL | 11.3286 mL | 22.6572 mL | |
5 mM | 0.4531 mL | 2.2657 mL | 4.5314 mL | |
10 mM | 0.2266 mL | 1.1329 mL | 2.2657 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.